Differences in Receptor Binding of LDL Subfractions
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Abstract Differences in low density lipoprotein (LDL) receptor-binding affinity among LDL particles of different size were examined in competitive binding assays in human skin fibroblasts and LDL (d=1.020 to 1.050 g/mL) from subjects with a predominance of large (≥272 Å), medium (259 to 271 Å), and small (≤257 Å) LDL. Among 57 normolipidemic subjects with LDL cholesterol (-C) levels <160 mg/dL, binding affinity was reduced by 16% in those with predominantly large LDL and by 14% in those with small LDL compared with most subjects who had a predominance of medium-size LDL and in all LDL size subgroups in 66 subjects with LDL-C ≥160 mg/dL. Differences in LDL receptor-binding affinity were further investigated by using LDL density subfractions (I,d=1.026 to 1.032 g/mL; II,d=1.032 to 1.038 g/mL; and III,d=1.038 to 1.050 g/mL) from three subjects with predominantly large (pattern A) and small (pattern B) LDL particles. The binding affinity (Kd) of LDL-II was similar for patterns A and B (9.2±1.4 and 9.4±0.7, respectively) and 30% lower in LDL-III from both groups (P<.05). The binding affinity of LDL-I in pattern A (12.6±1.5 μg/mg) was lower (P<.05) than that in LDL-II and LDL-I from pattern B (8.0±2.4 μg/mg). After incubation with a monoclonal antibody that specifically blocked the LDL receptor-binding domain of apoE, LDL-I from two pattern B subjects showed substantially lower binding affinity (Kd=20.0 and 19.2 μg/mg) than in pattern A (Kd=13.2 and 14.2 μg/mg), a result consistent with our finding of a higher apoE content in pattern B LDL-I (P<.001). Thus, factors associated with variations in particle size and apoE content in LDL subclasses in normolipidemic subjects contribute to the differences in LDL receptor binding that may result in differing metabolic behavior in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Self-citationHeiss, G., Tamir, I., Davis, C. E., Tyroler, H. A., Rifkand, B. M., Schonfeld, G., Jacobs, D., & Frantz, I. D. (1980) · Circulation · doi:10.1161/01.cir.61.2.302 · Cited by 526
Lipoprotein-receptor interactions
Innerarity, T. L., Pitas, R. E., & Mahley, R. W. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)29091-6 · Cited by 186
Self-citation
Cited by
Role of ROS and RNS Sources in Physiological and Pathological Conditions
Di Meo, S., Reed, T. T., Venditti, P., & Victor, V. M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1245049 · Cited by 1,614
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
“Chancharme L, Thérond P, Nigon F, Lepage S, Couturier M, Chapman MJ. Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. Arterioscler Thromb Vasc Biol 1999;19:810–820.”
BackgroundInfluentialSelf-citationMetabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
“As noted above, reduced LDL receptor binding has been reported for more buoyant and more dense LDL in comparison with intermediate density LDL subspecies (124, 125), which is in concordance of the finding of reduced LDL fractional catabolic rate in pattern B subjects (67).”
ResultSelf-citationLipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 756
Self-citationShim, H., Chasman, D. I., Smith, J. D., Mora, S., Ridker, P. M., Nickerson, D. A., Krauss, R. M., & Stephens, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120758 · Cited by 558
Self-citationStructure of apolipoprotein B-100 in low density lipoproteins
Segrest, J. P., Jones, M. K., De Loof, H., & Dashti, N. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30267-4 · Cited by 522
Lipoprotein Heterogeneity and Apolipoprotein B Metabolism
Packard, C. J., & Shepherd, J. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.12.3542 · Cited by 402
Mora, S., Szklo, M., Otvos, J. D., Greenland, P., Psaty, B. M., Goff, D. C., O’Leary, D. H., Saad, M. F., Tsai, M. Y., & Sharrett, A. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.007 · Cited by 380
Postmus, I., Trompet, S., Deshmukh, H. A., Barnes, M. R., Li, X., Warren, H. R., Chasman, D. I., Zhou, K., Arsenault, B. J., Donnelly, L. A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6068 · Cited by 267
Self-citationLow-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
Sacks, F. M., & Campos, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030636 · Cited by 241
Self-citationEffects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans
Reyes-Soffer, G., Pavlyha, M., Ngai, C., Thomas, T., Holleran, S., Ramakrishnan, R., Karmally, W., Nandakumar, R., Fontanez, N., Obunike, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025253 · Cited by 240
Tribble, D. L., Rizzo, M., Chait, A., Lewis, D. M., Blanche, P. J., & Krauss, R. M. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00700-2 · Cited by 185
Self-citationBergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
Self-citationDyslipidemia and Pediatric Obesity
Cook, S., & Kavey, R. E. W. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.09.003 · Cited by 165
“elevated total circulating LDL particles heighten the risk of entrapment in the subendothelial matrix, and decreased large HDL particles limit reverse cholesterol transport.(24,25) The atherogenicity of the combined dyslipidemia seen with childhood”
Metabolic abnormalities: triglyceride and low-density lipoprotein
Krauss, R. M., & Siri, P. W. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.016 · Cited by 102
Self-citationBays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Watts, G. F., Chan, D. C., Dent, R., Somaratne, R., Wasserman, S. M., Scott, R., Burrows, S., & R. Barrett, P. H. (2017) · Circulation · doi:10.1161/circulationaha.116.025080 · Cited by 93
Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use
Mora, S. (2009) · Circulation · doi:10.1161/circulationaha.108.819359 · Cited by 89
Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.11.009 · Cited by 46
The structure of apolipoprotein B100 from human low-density lipoprotein
Berndsen, Z. T., & Cassidy, C. K. (2025) · Nature · doi:10.1038/s41586-024-08467-w · Cited by 43
The Structure of ApoB100 from Human Low-density Lipoprotein
Berndsen, Z. T., & Cassidy, C. K. (2024) · doi:10.1101/2024.02.28.582555 · Cited by 43
Metadata
- Authors
- Campos, H., Arnold, K. S., Balestra, M. E., Innerarity, T. L., & Krauss, R. M.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1996-06
- Volume
- 16
- Issue
- 6
- Pages
- 794-801
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2007576831
- Cited by
- 112
- References
- 5
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.